Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (3228)	7/28/2015 10:48:54 AM
From: scaram(o)uche	Respond to of 3661

Some believe that chronic pot smokers don't have much of an issue with lung fibrosis. Don't know if it holds on close inspection.

To: tuck who wrote (3228)	3/30/2017 10:48:55 AM
From: tuck	Respond to of 3661

Corbus (CRBP) off 15% now on "positive" CF trial data. Positive data could just as easily have been background therapy of Vertex drugs, and events #s tiny. No lung function data supplied. Adam F. talks of imbalances in the arms. The company's scleroderma data were equivocal, but good enough to goose the stock. Harder to argue against Adam this time. I sold the scleroderma data, too, and I don't regret it. Not a buying opportunity, IMO. Cheers, Tuck